Twist Bioscience Surges as Lilly AI Deal Fuels Bullish Targets

Twist Bioscience Corporation stocks have been trading up by 7.38 percent following a pivotal synthetic biology technology breakthrough.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading TWST

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

What Traders Need To Know

Lilly TuneLab agreement plugs Twist Bioscience data and antibody services directly into Eli Lilly’s AI drug discovery stack, deepening exposure to AI-driven pharma workflows.
Shares climbed roughly 1.5% to more than 4% on the Lilly news, signaling traders are willing to chase TWST on AI-related catalysts.
Leerink twice lifted its TWST price target in 2026/09, now at $190 with an Outperform rating tied to conservative guidance and stronger pharma adoption.
Guggenheim and Barclays each more than doubled their TWST targets, up to $212 and $215, positioning the name as a core AI life sciences winner despite rich sector valuations.
Management frames Twist Bioscience as a picks-and-shovels supplier to AI drug discovery, with strong revenue growth, better margins, and a path to adjusted EBITDA breakeven by Q4 FY26.

Weekly Update Oct 05 – Oct 09, 2026: On Friday, October 09, 2026 Twist Bioscience Corporation stock [NASDAQ: TWST] is trending up by 7.38%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – positive

Twist Bioscience occupies a differentiated position in synthetic biology and NGS tools, with 52% gross margin and ~10% three-year revenue CAGR, decelerating from a very strong five-year base. However, EBIT margin at -31.8% and ROE around -30% highlight a still-immature profit model. The balance sheet is solid for a high-growth tools name: net cash, current ratio 2.7, modest leverage. The 23.9x sales and 23x book multiples embed aggressive long-term scaling and margin expansion assumptions.

Technically, TWST remains in a strong, extended uptrend but is showing volatility and some digestion after the vertical re-rate. The weekly range from 205.25 down to 150.73 and back toward 160 underscores profit-taking off stretched levels while preserving higher lows versus prior months. Intraday 5-minute action shows heavy volume spikes near 150–155 being bought, defining a key support zone. For trading, 150 is the actionable level: long bias above 150 with tight risk control below 145.

More Breaking News

Catalysts are clearly skewed to the upside: the Lilly TuneLab partnership and emerging AI protein-design work with Anthropic reinforce Twist as a critical data and infrastructure layer for AI-enabled drug discovery, driving multiple analyst target hikes to $190–215. Compared with broader Healthcare and Diagnostics peers, TWST trades at a premium but also offers faster growth and earlier AI leverage. I see upside continuation with next resistance near 200–210 and strong support at 145–150.

Quick Financial Overview

Twist Bioscience Corporation (TWST) is trading in an elevated zone after a strong AI and pharma narrative. Weekly data show the stock pulling back from about $205 to the mid-$150s, then bouncing to roughly $160–$166. That pattern tells you this is a momentum name that just went through a fast repricing and is now consolidating. Intraday, the tape around $160 shows tight two-way action, with repeated pushes into the low $160s getting sold, which marks that band as short-term resistance.

On fundamentals, TWST printed about $376.6M in revenue over the trailing period, with roughly 52% gross margin but still heavy operating losses. Profitability ratios are deeply negative, with an EBIT margin near -31.8% and return on equity close to -30%, which fits a high-growth, pre-profit profile. The cash flow statement confirms this: TWST ran negative free cash flow of about $8.6M last quarter, but operating cash flow flipped slightly positive at roughly $1.1M, helped by stock-based compensation and working-capital shifts.

The balance sheet is a key piece for traders. Cash and short-term investments sit around $166.8M, with long-term debt under $100M and a current ratio of about 2.7, giving the company a solid liquidity runway. Valuation, however, is stretched by standard metrics: price-to-sales is near 23.9 and price-to-book around 23.15, reflecting the market’s willingness to pay up for AI leverage and platform potential. With enterprise value over $10.0B and no meaningful earnings yet, this is a sentiment and growth-driven story, not a value play.

Conclusion

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!